Get Live Index Option Trades
gift nifty image banner
Want a perfect stocks portfolio for 2026? Create Now
BUSINESS

AstraZeneca Pharma India Signs LoI With Reliance Unit Strand

AstraZeneca
AstraZeneca Pharma India signed a letter of intent with Reliance unit Strand Life Sciences

AstraZeneca Pharma India signed a letter of intent with Reliance unit Strand Life Sciences to explore healthcare collaboration in India.

The drugmaker told BSE and NSE about the pact in a filing on Tuesday 17 November. Strand is a diagnostics and gene-research company.

A letter of intent is usually an early-stage paper. It says two parties plan to work together, and the details come later. No deal value has been reported.

AstraZeneca also said that Strand, a Reliance Industries subsidiary, is not a related party, so the signing is not a related party transaction.

In plain terms, the two companies do not share the kind of ties that call for special disclosure.

In a LinkedIn post, the company said it remains committed to clearing the hurdles that delay diagnosis and to improving cancer care across India. The two firms already know each other.

In July, AstraZeneca India signed an agreement with the Andhra Pradesh government to set up a genomic testing centre in Amaravati, to be built with Strand and the health-tech firm Qure.ai.

It will offer gene-based tests for lung and breast cancer patients. The reports on the new letter do not say whether it links to that project.

On 7 November, the company said it will launch Datverzo, a treatment for a specific type of advanced breast cancer, in India this month.

It is meant for patients whose cancer has spread or cannot be removed by surgery and who have already tried hormone-based therapy and chemotherapy. On 5 November, it reported results for July to September.

Profit after tax rose 14.96% to Rs 62.33 crore from Rs 54.22 crore a year earlier, while revenue from operations climbed 30.41% to Rs 729.1 crore from Rs 559.09 crore.

Praveen Rao Akkinepally, the company’s country president and managing director, said the focus is on building partnerships across healthcare so new medicines reach more patients sooner.

Not sure when to enterβ€”or when to exit? Get defined trade levels and live follow-up updates from a SEBI-registered Research Analyst. Download the IDT app today.

Click here to check market prediction for next trading session.




πŸ“°
News
πŸ“ˆ
Prediction
πŸ“Š
FII / DII
πŸ’Ό
Portfolio 2026